156 related articles for article (PubMed ID: 37594231)
1. A novel Nlrp3 knock-in mouse model with hyperactive inflammasome in development of lethal inflammation.
Zhou Y; Yang X; Zhu L
Clin Exp Immunol; 2024 Feb; 215(2):202-214. PubMed ID: 37594231
[TBL] [Abstract][Full Text] [Related]
2. A Novel Mutation in the Pyrin Domain of the NOD-like Receptor Family Pyrin Domain Containing Protein 3 in Muckle-Wells Syndrome.
Hu J; Zhu Y; Zhang JZ; Zhang RG; Li HM
Chin Med J (Engl); 2017 Mar; 130(5):586-593. PubMed ID: 28229991
[TBL] [Abstract][Full Text] [Related]
3. A novel knock-in mouse model of cryopyrin-associated periodic syndromes with development of amyloidosis: Therapeutic efficacy of proton pump inhibitors.
Bertoni A; Carta S; Baldovini C; Penco F; Balza E; Borghini S; Di Duca M; Ognio E; Signori A; Nozza P; Schena F; Castellani P; Pastorino C; Perrone C; Obici L; Martini A; Ceccherini I; Gattorno M; Rubartelli A; Chiesa S
J Allergy Clin Immunol; 2020 Jan; 145(1):368-378.e13. PubMed ID: 31194989
[TBL] [Abstract][Full Text] [Related]
4. Nlrp3 inflammasome activation in macrophages suffices for inducing autoinflammation in mice.
Frising UC; Ribo S; Doglio MG; Malissen B; van Loo G; Wullaert A
EMBO Rep; 2022 Jul; 23(7):e54339. PubMed ID: 35574994
[TBL] [Abstract][Full Text] [Related]
5. MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition.
Vande Walle L; Stowe IB; Šácha P; Lee BL; Demon D; Fossoul A; Van Hauwermeiren F; Saavedra PHV; Šimon P; Šubrt V; Kostka L; Stivala CE; Pham VC; Staben ST; Yamazoe S; Konvalinka J; Kayagaki N; Lamkanfi M
PLoS Biol; 2019 Sep; 17(9):e3000354. PubMed ID: 31525186
[TBL] [Abstract][Full Text] [Related]
6.
Nakanishi H; Kawashima Y; Kurima K; Chae JJ; Ross AM; Pinto-Patarroyo G; Patel SK; Muskett JA; Ratay JS; Chattaraj P; Park YH; Grevich S; Brewer CC; Hoa M; Kim HJ; Butman JA; Broderick L; Hoffman HM; Aksentijevich I; Kastner DL; Goldbach-Mansky R; Griffith AJ
Proc Natl Acad Sci U S A; 2017 Sep; 114(37):E7766-E7775. PubMed ID: 28847925
[TBL] [Abstract][Full Text] [Related]
7. KN3014, a piperidine-containing small compound, inhibits auto-secretion of IL-1β from PBMCs in a patient with Muckle-Wells syndrome.
Kaneko N; Kurata M; Yamamoto T; Shigemura T; Agematsu K; Yamazaki T; Takeda H; Sawasaki T; Koga T; Kawakami A; Yachie A; Migita K; Yoshiura KI; Urano T; Masumoto J
Sci Rep; 2020 Aug; 10(1):13562. PubMed ID: 32782316
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effect of NLRP3 inhibition on hearing loss induced by systemic inflammation in a CAPS-associated mouse model.
Ma JH; Lee E; Yoon SH; Min H; Oh JH; Hwang I; Sung Y; Ryu JH; Bok J; Yu JW
EBioMedicine; 2022 Aug; 82():104184. PubMed ID: 35870427
[TBL] [Abstract][Full Text] [Related]
9. Human NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase.
Liu X; Pichulik T; Wolz OO; Dang TM; Stutz A; Dillen C; Delmiro Garcia M; Kraus H; Dickhöfer S; Daiber E; Münzenmayer L; Wahl S; Rieber N; Kümmerle-Deschner J; Yazdi A; Franz-Wachtel M; Macek B; Radsak M; Vogel S; Schulte B; Walz JS; Hartl D; Latz E; Stilgenbauer S; Grimbacher B; Miller L; Brunner C; Wolz C; Weber ANR
J Allergy Clin Immunol; 2017 Oct; 140(4):1054-1067.e10. PubMed ID: 28216434
[TBL] [Abstract][Full Text] [Related]
10. CANE, a Component of the NLRP3 Inflammasome, Promotes Inflammasome Activation.
Kaneko N; Kurata M; Yamamoto T; Sakamoto A; Takada Y; Kosako H; Takeda H; Sawasaki T; Masumoto J
J Immunol; 2024 Jul; 213(1):86-95. PubMed ID: 38787200
[TBL] [Abstract][Full Text] [Related]
11. Prim-O-glucosycimifugin attenuates liver injury in septic mice by inhibiting NLRP3 inflammasome/caspase-1 signaling cascades in macrophages.
Liu LL; Yan X; Xue KY; Wang XM; Li LY; Chen HY; Li RL; Li H; Lan J; Xin JJ; Li X; Zhuo CL; Wu Z; Zhang D; Huang WJ; Wang YL; Li XY; Jiang W; Zhang HY
Phytomedicine; 2022 Nov; 106():154427. PubMed ID: 36088791
[TBL] [Abstract][Full Text] [Related]
12. Antisense Oligonucleotide Therapy Decreases IL-1β Expression and Prolongs Survival in Mutant Nlrp3 Mice.
Kaufmann B; de Los Reyes Jiménez M; Booshehri LM; Onyuru J; Leszczynska A; Uri A; Michel S; Klar R; Jaschinski F; Feldstein AE; Broderick L; Hoffman HM
J Immunol; 2023 Jul; 211(2):287-294. PubMed ID: 37256266
[TBL] [Abstract][Full Text] [Related]
13. Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies.
Brydges SD; Broderick L; McGeough MD; Pena CA; Mueller JL; Hoffman HM
J Clin Invest; 2013 Nov; 123(11):4695-705. PubMed ID: 24084736
[TBL] [Abstract][Full Text] [Related]
14. Engineered Pigs Carrying a Gain-of-Function NLRP3 Homozygous Mutation Can Survive to Adulthood and Accurately Recapitulate Human Systemic Spontaneous Inflammatory Responses.
Li W; Shi L; Zhuang Z; Wu H; Lian M; Chen Y; Li L; Ge W; Jin Q; Zhang Q; Zhao Y; Liu Z; Ouyang Z; Ye Y; Li Y; Wang H; Liao Y; Quan L; Xiao L; Lai L; Meng G; Wang K
J Immunol; 2020 Nov; 205(9):2532-2544. PubMed ID: 32958688
[TBL] [Abstract][Full Text] [Related]
15. CARD8 is a negative regulator for NLRP3 inflammasome, but mutant NLRP3 in cryopyrin-associated periodic syndromes escapes the restriction.
Ito S; Hara Y; Kubota T
Arthritis Res Ther; 2014 Feb; 16(1):R52. PubMed ID: 24517500
[TBL] [Abstract][Full Text] [Related]
16. TNF regulates transcription of NLRP3 inflammasome components and inflammatory molecules in cryopyrinopathies.
McGeough MD; Wree A; Inzaugarat ME; Haimovich A; Johnson CD; Peña CA; Goldbach-Mansky R; Broderick L; Feldstein AE; Hoffman HM
J Clin Invest; 2017 Dec; 127(12):4488-4497. PubMed ID: 29130929
[TBL] [Abstract][Full Text] [Related]
17. CAPS and NLRP3.
Booshehri LM; Hoffman HM
J Clin Immunol; 2019 Apr; 39(3):277-286. PubMed ID: 31077002
[TBL] [Abstract][Full Text] [Related]
18. Selective inhibition of NLRP3 inflammasome by designed peptide originating from ASC.
Sušjan P; Lainšček D; Strmšek Ž; Hodnik V; Anderluh G; Hafner-Bratkovič I
FASEB J; 2020 Aug; 34(8):11068-11086. PubMed ID: 32648626
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology of a Potent and Novel Inhibitor of the NOD-Like Receptor Pyrin Domain-Containing Protein 3 (NLRP3) Inflammasome that Attenuates Development of Nonalcoholic Steatohepatitis and Liver Fibrosis.
Povero D; Lazic M; McBride C; Ambrus-Aikelin G; Stansfield R; Johnson CD; Santini AM; Pranadinata RF; McGeough MD; Stafford JA; Hoffman HM; Feldstein AE; Veal JM; Bain G
J Pharmacol Exp Ther; 2023 Aug; 386(2):242-258. PubMed ID: 37308266
[TBL] [Abstract][Full Text] [Related]
20. NLRP3 mediates osteolysis through inflammation-dependent and -independent mechanisms.
Qu C; Bonar SL; Hickman-Brecks CL; Abu-Amer S; McGeough MD; Peña CA; Broderick L; Yang C; Grimston SK; Kading J; Abu-Amer Y; Novack DV; Hoffman HM; Civitelli R; Mbalaviele G
FASEB J; 2015 Apr; 29(4):1269-79. PubMed ID: 25477279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
